DURHAM, N.C., April 12, 2016 — Study of acute pain drugs can benefit greatly from preclinical research. Premier Research will explain why and how in a webinar on Tuesday, April 12. The hour-long event will begin at 11 a.m. EDT / 4 p.m. BST / 5 p.m. CEST.
Evaluating a medication for acute pain typically starts with a single-dose analgesic study that determines proof of concept, effective dose range, analgesic properties, and duration of effect. Michael Kuss, our Vice President of Analgesia, will describe how preclinical research can provide important clues about models and study designs when he presents Research Design Considerations for Single-Dose Analgesic Clinical Trials in Acute Pain.
Kuss will review a recent article in the journal Pain and discuss key considerations for any acute pain analgesic study:
- Efficacy and safety in acute pain models.
- General research design, including the value of a placebo treatment arm.
- Considerations around proof of concept and dose-ranging.
- Choosing the right active comparator.
About Premier Research
Premier Research is a leading contract research organization serving the needs of biotechnology, pharmaceutical and medical device companies worldwide. The company has a wealth of experience in the execution of global, regional, and local clinical development programs with a special focus on addressing unmet needs in such areas as analgesia, CNS, rare diseases, medical device and diagnostics, oncology, and pediatric. Premier Research operates in 84 countries and employs more than 1,000 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. With its mission to improve productivity in clinical development, the company aligns itself with the mission of its customers to bring new medical treatments to patients promptly, accurately, and cost-effectively.